Vertex Ventures

VIVUS Inc., now operating as VIVUS LLC, is a biopharmaceutical company committed to developing and commercializing innovative therapies for serious medical conditions. Founded in 1991 and headquartered in Campbell, California, VIVUS has a focused strategy on addressing unmet medical needs through a diverse portfolio of products and pipeline developments. VIVUS's product portfolio includes Qsymia®, a weight management medication approved in the U.S. and South Korea, which has shown efficacy in reducing blood pressure and managing weight in adolescents and adults. They have also developed PANCREAZE®, a pancreatic enzyme replacement therapy used to treat exocrine pancreatic insufficiency (EPI) caused by conditions like cystic fibrosis. The company's investment strategy involves acquiring and managing revenue-generating products. They focus on expanding their commercial footprint globally, as seen with their strategic partnerships and product launches in markets like South Korea. Key team members include John Amos, CEO, and Santosh Varghese, MD, President and Chief Medical Officer, who bring extensive experience in the pharmaceutical industry to drive VIVUS's mission forward​.